1. Home
  2. DERM vs IMUX Comparison

DERM vs IMUX Comparison

Compare DERM & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Journey Medical Corporation

DERM

Journey Medical Corporation

BUY

Current Price

$6.19

Market Cap

190.3M

Sector

Health Care

ML Signal

BUY

Logo Immunic Inc.

IMUX

Immunic Inc.

BUY

Current Price

$7.84

Market Cap

155.8M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
DERM
IMUX
Founded
2014
2016
Country
United States
United States
Employees
N/A
66
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
155.8M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
DERM
IMUX
Price
$6.19
$7.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
12
Target Price
$13.75
★ $43.09
AVG Volume (30 Days)
175.0K
★ 390.3K
Earning Date
11-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
34.72
★ 38.00
EPS
★ N/A
N/A
Revenue
★ $61,858,000.00
N/A
Revenue This Year
$31.55
N/A
Revenue Next Year
$60.28
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 10.20
N/A
52 Week Low
$4.31
$0.51
52 Week High
$9.56
$17.43

Technical Indicators

Market Signals
Indicator
DERM
IMUX
Relative Strength Index (RSI) 37.92 23.86
Support Level $5.95 $0.78
Resistance Level $6.59 $15.82
Average True Range (ATR) 0.41 0.66
MACD -0.07 -0.11
Stochastic Oscillator 9.18 2.51

Price Performance

Historical Comparison
DERM
IMUX

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: